Despite preventive treatment, HAE patients require on-demand care
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…
Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.
New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…
Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…
People with hereditary angioedema (HAE) are able to recognize early signs of swelling attacks and the need to get prompt on-demand treatment to manage them, new research highlights. Findings were presented by KalVista Pharmaceuticals in a series of posters at the recent U.S. Hereditary Angioedema Association (HAEA)…
BioCryst Pharmaceuticals is teaming up with Er-Kim Pharmaceuticals to commercialize Orladeyo (berotralstat) in Turkey. Orladeyo is an oral therapy, taken once a day, to prevent swelling attacks with hereditary angioedema (HAE). Er-Kim, based in Istanbul, partners with pharma companies to bring new therapies to markets around…
A woman still doesn’t have a definitive answer as to the underlying cause of her angioedema after more than a decade of recurrent facial swelling, underscoring the difficulties in diagnosing the condition. “This case report demonstrates the challenge of the differential diagnosis of angioedema without wheals,” the researchers wrote…
Get regular updates to your inbox.